128 related articles for article (PubMed ID: 26431981)
21. The Impact of Varying Numbers of Quadrivalent Human Papillomavirus Vaccine Doses on Anogenital Warts in the United States: A Database Study.
Zeybek B; Lin YL; Kuo YF; Rodriguez AM
J Low Genit Tract Dis; 2018 Jul; 22(3):189-194. PubMed ID: 29762430
[TBL] [Abstract][Full Text] [Related]
22. Epidemiological impact of the human papillomavirus vaccination program on genital warts in Portugal: A retrospective, chart review study.
Fernandes C; Alves J; Rodrigues A; Azevedo J;
Vaccine; 2022 Jan; 40(2):275-281. PubMed ID: 34953608
[TBL] [Abstract][Full Text] [Related]
23. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease.
Lacey CJ; Lowndes CM; Shah KV
Vaccine; 2006 Aug; 24 Suppl 3():S3/35-41. PubMed ID: 16950016
[TBL] [Abstract][Full Text] [Related]
24. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
25. The prevalence of genital warts in the Baltic countries: findings from national cross-sectional surveys in Estonia, Latvia and Lithuania.
Uusküla A; Reile R; Rezeberga D; Karnite A; Logminiene Z; Padaiga Ž; Nygård M
Sex Transm Infect; 2015 Feb; 91(1):55-60. PubMed ID: 25104496
[TBL] [Abstract][Full Text] [Related]
26. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data.
Ali H; Donovan B; Wand H; Read TR; Regan DG; Grulich AE; Fairley CK; Guy RJ
BMJ; 2013 Apr; 346():f2032. PubMed ID: 23599298
[TBL] [Abstract][Full Text] [Related]
27. Self-reported genital warts among sexually-active university students: a cross-sectional study.
Cocchio S; Bertoncello C; Baldovin T; Buja A; Majori S; Baldo V
BMC Infect Dis; 2018 Jan; 18(1):41. PubMed ID: 29334908
[TBL] [Abstract][Full Text] [Related]
28. Genital warts in men: a large population-based cross-sectional survey of Danish men.
Munk C; Nielsen A; Liaw KL; Kjaer SK
Sex Transm Infect; 2012 Dec; 88(8):640-4. PubMed ID: 22941865
[TBL] [Abstract][Full Text] [Related]
29. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine.
Nsouli-Maktabi H; Ludwig SL; Yerubandi UD; Gaydos JC
MSMR; 2013 Feb; 20(2):17-20. PubMed ID: 23461306
[TBL] [Abstract][Full Text] [Related]
30. Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations.
Camenga DR; Dunne EF; Desai MM; Gee J; Markowitz LE; Desiliva A; Klein NP
Sex Transm Dis; 2013 Jul; 40(7):534-8. PubMed ID: 23965766
[TBL] [Abstract][Full Text] [Related]
31. Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study.
Cocchio S; Baldovin T; Bertoncello C; Buja A; Furlan P; Saia M; Baldo V
BMC Infect Dis; 2017 Apr; 17(1):249. PubMed ID: 28381294
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus, genital warts, and vaccines.
Hsueh PR
J Microbiol Immunol Infect; 2009 Apr; 42(2):101-6. PubMed ID: 19597640
[TBL] [Abstract][Full Text] [Related]
33. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
[TBL] [Abstract][Full Text] [Related]
34. [Epidemiology of genital warts in female population of Czech Republic].
Fait T; Dvořák V; Skřivánek A; Rokyta Z; Pilka R
Ceska Gynekol; 2012 Aug; 77(4):360-3. PubMed ID: 23094779
[TBL] [Abstract][Full Text] [Related]
35. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
36. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme.
Read TR; Hocking JS; Chen MY; Donovan B; Bradshaw CS; Fairley CK
Sex Transm Infect; 2011 Dec; 87(7):544-7. PubMed ID: 21970896
[TBL] [Abstract][Full Text] [Related]
37. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
38. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males.
Korostil IA; Ali H; Guy RJ; Donovan B; Law MG; Regan DG
Sex Transm Dis; 2013 Nov; 40(11):833-5. PubMed ID: 24113401
[TBL] [Abstract][Full Text] [Related]
39. Is use of the human papillomavirus vaccine among female college students related to human papillomavirus knowledge and risk perception?
Licht AS; Murphy JM; Hyland AJ; Fix BV; Hawk LW; Mahoney MC
Sex Transm Infect; 2010 Feb; 86(1):74-8. PubMed ID: 19841004
[TBL] [Abstract][Full Text] [Related]
40. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
Yancey AM; Pitlick JM; Forinash AB
Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
